Study of FYU-981 in Hyperuricemia With or Without Gout
Launched by FUJI YAKUHIN CO., LTD. · Jan 22, 2015
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hyperuricemic or gout patients
- * Serum urate level:
- • \>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL
- Exclusion Criteria:
- • Gouty arthritis within two weeks before start of study treatment
- • Secondary hyperuricemia
- • HbA1c: \>= 8.4%
- • Uric acid-overproduction type in the classification of hyperuricemia
- • History of, clinically significant cardiac, hematologic and hepatic disease
- • Kidney calculi or clinically significant urinary calculi
- • eGFR: \< 60mL/min/1.73m\^2
- • Systolic blood pressure: \>= 180 mmHg
- • Diastolic blood pressure: \>= 110 mmHg
About Fuji Yakuhin Co., Ltd.
Fuji Yakuhin Co., Ltd. is a leading pharmaceutical company based in Japan, dedicated to the development and manufacturing of innovative therapeutic solutions. With a strong focus on research and development, the company specializes in a diverse range of medical products, including generics and specialty pharmaceuticals. Committed to enhancing global health, Fuji Yakuhin collaborates with healthcare professionals and regulatory bodies to ensure the highest standards of safety and efficacy in its clinical trials. The company's mission is to contribute to patient care through cutting-edge research, quality manufacturing, and a robust pipeline of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials